Sellas Life Sciences
在场
Sellas Life Sciences 是一家在股票代码 SLS (CH) 下上市的公司。
高管
查看带有其 10 名主要高管的组织结构图
Sellas Life Sciences 搜索最多的简介
- Angelos Stergiou, Chief Executive Officer and Director
- Jane Wasman, Chairman of the Board
- David Scheinberg, Director
创建提醒
跟踪 Sellas Life Sciences 的高管变动
健康
Sellas Life Sciences 拥有 2,001 家竞争者，其中包括 UnitedHealth Group (美国(美洲))、UnitedHealthcare (美国(美洲)) 和 Siemens Healthineers (德国)。
Popular M&A news in 健康
- CCC Intelligent Solutions has announced the acquisition of EvolutionIQ (公布2024十二月31号).
- Oura Health 刚刚宣布为 200 筹款数百万美元。 (公布2024十二月20号).
- Neuronetics 已收购 Greenbrook TMS (公布2024十二月10号).
健康 行业的其他推荐联系人
消息
Sellas Life Sciences 的最新新闻稿
- SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
- SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
- SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
- SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
- SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
- SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
- SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
- SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
- View more press releases Close
通过电子邮件
